Last reviewed · How we verify
Combined metabolic activators — Competitive Intelligence Brief
phase 3
Metabolic Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Combined metabolic activators (Combined metabolic activators) — ScandiBio Therapeutics AB. Combined metabolic activators enhance cellular energy production and metabolic efficiency by simultaneously activating multiple metabolic pathways.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Combined metabolic activators TARGET | Combined metabolic activators | ScandiBio Therapeutics AB | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Combined metabolic activators CI watch — RSS
- Combined metabolic activators CI watch — Atom
- Combined metabolic activators CI watch — JSON
- Combined metabolic activators alone — RSS
Cite this brief
Drug Landscape (2026). Combined metabolic activators — Competitive Intelligence Brief. https://druglandscape.com/ci/combined-metabolic-activators. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab